Entellus Medical Inc (NASDAQ:ENTL) insider Robert S. White sold 3,471 shares of the firm’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $24.01, for a total transaction of $83,338.71. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Entellus Medical Inc (NASDAQ ENTL) traded down $0.06 during mid-day trading on Tuesday, reaching $24.07. 216,202 shares of the company’s stock were exchanged, compared to its average volume of 236,460. The company has a quick ratio of 1.71, a current ratio of 1.92 and a debt-to-equity ratio of 0.32. Entellus Medical Inc has a 52 week low of $11.47 and a 52 week high of $25.58. The stock has a market capitalization of $613.16 and a price-to-earnings ratio of -18.80.
Entellus Medical (NASDAQ:ENTL) last posted its quarterly earnings data on Wednesday, November 1st. The medical technology company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.02. Entellus Medical had a negative net margin of 31.24% and a negative return on equity of 47.37%. analysts forecast that Entellus Medical Inc will post -1.33 EPS for the current year.
A number of hedge funds have recently bought and sold shares of the business. Neuberger Berman Group LLC lifted its stake in Entellus Medical by 152.2% during the third quarter. Neuberger Berman Group LLC now owns 58,000 shares of the medical technology company’s stock valued at $1,071,000 after buying an additional 35,000 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Entellus Medical by 74.7% in the third quarter. Wells Fargo & Company MN now owns 11,329 shares of the medical technology company’s stock worth $209,000 after purchasing an additional 4,846 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Entellus Medical in the third quarter worth approximately $302,000. Archon Capital Management LLC lifted its position in shares of Entellus Medical by 14.9% in the third quarter. Archon Capital Management LLC now owns 550,224 shares of the medical technology company’s stock worth $10,157,000 after purchasing an additional 71,404 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Entellus Medical by 145.1% in the third quarter. JPMorgan Chase & Co. now owns 9,469 shares of the medical technology company’s stock worth $168,000 after purchasing an additional 5,605 shares in the last quarter. 78.24% of the stock is owned by institutional investors.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.